Want to see AU:NSB full AI Analyst Report?
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$24.94M
Enterprise ValueAU$19.56M
Total Cash (Recent Filing)AU$7.27M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding389,718,540
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces solvency risk and eliminates interest expense, giving management structural flexibility to direct limited cash toward R&D, licensing or milestone spend. Over 2–6 months this supports resilience to funding volatility and improves partnerability.
Positive Equity BaseSustained positive equity provides a cushion for ongoing investment and makes balance-sheet financing or equity raises less disruptive than for insolvent peers. This supports longer-term ability to pursue clinical programs or secure collaboration funding without immediate solvency strain.
Focused Neuroscience R&D And Lean TeamA clear, niche R&D focus in neuroscience and a small, lean team imply concentrated domain expertise and lower fixed overhead. Structurally this can enable targeted trial programs, easier partnering/licensing conversations, and more efficient use of scarce cash over the medium term.
Bears Say
Revenue Collapse And VolatilityA move to zero annual revenue removes internal funding for operations and indicates weak commercial traction. Over the next several months this heightens reliance on external funding or partnerships, increases execution risk for trials, and undermines sustainable product commercialization prospects.
Consistent Cash BurnPersistent negative operating and free cash flow create a structural runway problem: management must secure financing or non-dilutive partnerships. This ongoing burn elevates dilution risk, can delay programs if funding tightens, and constrains strategic optionality across the medium term.
Recurring Operating LossesSustained operating losses show the business is not yet self-sustaining and will likely rely on capital markets or partners. Over 2–6 months, continued unprofitability pressures credibility with investors and potential collaborators, raising the bar for milestone-based or equity financing.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.06 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$24.94M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 59 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 389,718,540 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-19.10%
Trailing 12-Months
Asset Growth
232.64%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Island Pharmaceuticals Ltd
―
AnteoTech Ltd
―
Options Prices
Currently, No data available
---